Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 2
2015 3
2016 2
2017 7
2018 9
2019 14
2020 31
2021 59
2022 63
2023 59
2024 74
2025 81
2026 48

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

383 results

Results by year

Filters applied: . Clear all
Page 1
Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Douglas RS, et al. N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434. N Engl J Med. 2020. PMID: 31971679 Clinical Trial.
BACKGROUND: Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food and Drug Administration-approved medical therapy is available. ...CONCLUSIONS: Among patients with active thyroid eye …
BACKGROUND: Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which …
Teprotumumab: A Review in Thyroid Eye Disease.
Nie T, Lamb YN. Nie T, et al. Drugs. 2022 Nov;82(17):1663-1670. doi: 10.1007/s40265-022-01804-1. Epub 2022 Nov 23. Drugs. 2022. PMID: 36418673 Free PMC article. Review.
Teprotumumab (TEPEZZA( )), a monoclonal antibody that inhibits the insulin-like growth factor 1 receptor (IGF-1R), is the first disease-modifying therapy approved for the treatment of thyroid eye disease (TED) in the USA. ...While further data a …
Teprotumumab (TEPEZZA( )), a monoclonal antibody that inhibits the insulin-like growth factor 1 receptor (IGF-1R), is the first di …
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ. Douglas RS, et al. Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21. Ophthalmology. 2022. PMID: 34688699 Free article. Clinical Trial.
PURPOSE: To evaluate teprotumumab safety/efficacy in patients with thyroid eye disease (TED) who were nonresponsive or who experienced a disease flare. DESIGN: The Treatment of Graves' Orbitopathy to Reduce Proptosis with Teprotumumab …
PURPOSE: To evaluate teprotumumab safety/efficacy in patients with thyroid eye disease (TED) who were nonrespons …
Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.
Wiersinga WM, Eckstein AK, Žarković M. Wiersinga WM, et al. Lancet Diabetes Endocrinol. 2025 Jul;13(7):600-614. doi: 10.1016/S2213-8587(25)00066-X. Epub 2025 May 2. Lancet Diabetes Endocrinol. 2025. PMID: 40324443 Review.
Thyroid eye disease (TED; also known as Graves' orbitopathy), causes swollen extraocular muscles and orbital fat. ...Investigation of TED involves assessment of disease activity (inflammation) and disease severity. TED is predominantly mi …
Thyroid eye disease (TED; also known as Graves' orbitopathy), causes swollen extraocular muscles and orbital fat …
Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS, Tang R, Nguyen QT, Maamari RN, Ugradar S, Hsu K, Karon M, Stan MN. Douglas RS, et al. J Clin Endocrinol Metab. 2023 Dec 21;109(1):25-35. doi: 10.1210/clinem/dgad637. J Clin Endocrinol Metab. 2023. PMID: 37925673 Free PMC article. Clinical Trial.
CONTEXT: Early inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabling proptosis. ...There were no deaths. CONCLUSION: Teprotumumab significantly improved proptosis vs placebo in longstanding/low infla …
CONTEXT: Early inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabli …
Teprotumumab for the Treatment of Thyroid Eye Disease.
Ugradar S, Malkhasyan E, Douglas RS. Ugradar S, et al. Endocr Rev. 2024 Nov 22;45(6):843-857. doi: 10.1210/endrev/bnae018. Endocr Rev. 2024. PMID: 38838219 Free article. Review.
Thyroid eye disease (TED) is the most common extra thyroidal manifestation of Graves' disease (GD). ...Since 2020, more than 5800 patients have been treated with teprotumumab, and it appears to be well tolerated. The American Thyroid …
Thyroid eye disease (TED) is the most common extra thyroidal manifestation of Graves' disease (GD). ...Si …
Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
Kahaly GJ, Subramanian PS, Conrad E, Holt RJ, Smith TJ. Kahaly GJ, et al. Thyroid. 2024 Jul;34(7):880-889. doi: 10.1089/thy.2023.0656. Epub 2024 Jun 2. Thyroid. 2024. PMID: 38824618 Free article. Clinical Trial.
Introduction: Thyroid eye disease (TED) is an autoimmune process characterized by extraocular muscle and orbital fat remodeling/expansion resulting in swelling, pain, redness, proptosis, and diplopia. ...Graves' Ophthalmopathy quality-of-life (G …
Introduction: Thyroid eye disease (TED) is an autoimmune process characterized by extraocular muscle and orbital fat re …
Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Shah SA, Amarikwa L, Sears CM, Clauss KD, Rajjoub RD, Kang JY, Tamhankar MA, Briceño CA, Harrison AR, Dosiou C, Cockerham KP, Wester ST, Douglas RS, Kossler AL. Shah SA, et al. Ophthalmology. 2024 Apr;131(4):458-467. doi: 10.1016/j.ophtha.2023.10.018. Epub 2023 Oct 16. Ophthalmology. 2024. PMID: 37852417 Free PMC article.
PURPOSE: To assess the duration, incidence, reversibility, and severity of adverse events (AEs) in patients with thyroid eye disease (TED) treated with teprotumumab. DESIGN: Multicenter, retrospective, observational cohort study. PARTICIPANTS: Patients …
PURPOSE: To assess the duration, incidence, reversibility, and severity of adverse events (AEs) in patients with thyroid eye …
Teprotumumab for Thyroid Eye Disease: Mechanism, Clinical Efficacy, and Current Challenges.
Zong Y, Qiu S, Yang M, Zhang J, Zou Y, Jing Y, Ohno-Matsui K, Kamoi K. Zong Y, et al. Antibodies (Basel). 2025 Jun 30;14(3):55. doi: 10.3390/antib14030055. Antibodies (Basel). 2025. PMID: 40700295 Free PMC article. Review.
Thyroid eye disease (TED) is a complex autoimmune disorder characterized by orbital inflammation and tissue remodeling. ...This review comprehensively analyzes the therapeutic role of teprotumumab in TED management. Mechanistically, teprotumumab …
Thyroid eye disease (TED) is a complex autoimmune disorder characterized by orbital inflammation and tissue remodeling. …
Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A Systematic Review and Meta-Analysis.
Huang W, Ou X, Lin S, Lin W, Chen G, Huang H, Wen J. Huang W, et al. Endocr Pract. 2025 May;31(5):640-649. doi: 10.1016/j.eprac.2025.01.012. Epub 2025 Feb 12. Endocr Pract. 2025. PMID: 39952471
OBJECTIVE: Teprotumumab was approved by the US Food and Drug Administration (FDA) for treating Graves' orbitopathy in adults on January 21, 2020. This study evaluates its efficacy and safety in treating thyroid eye disease (TED). METHODS: We rev …
OBJECTIVE: Teprotumumab was approved by the US Food and Drug Administration (FDA) for treating Graves' orbitopathy in adults o …
383 results